TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00454584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1275 45 mg
Description: Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1275 90 mg
Description: Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
Study: NCT02471040

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
Study: NCT00683657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5mg, once daily, 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 4 weeks
Study: NCT03875924

Intervention type: OTHER
Intervention: VWD treatments
Description: Modalities and types of treatments in VWD patients for severe hemorrhagic events: INN, quantities, duration of treatment
Study: NCT00454584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept 50 mg
Description: Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
Study: NCT02266576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard DPP
Description: The Standard Diabetes Prevention Program (DPP) delivered by the San Jose State Timpany Center is the Group Lifestyle Balance™ DPP, which has previously been tailored for urban American Indians and Alaska Natives by the Indian Health Service. Standard DPP components consist of 16 group classes, 4 visits with a lifestyle coach and access to a therapeutic swimming pool and gym.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard DPP
Description: The Standard Diabetes Prevention Program (DPP) delivered by the San Jose State Timpany Center is the Group Lifestyle Balance™ DPP, which has previously been tailored for urban American Indians and Alaska Natives by the Indian Health Service. Standard DPP components consist of 16 group classes, 4 visits with a lifestyle coach and access to a therapeutic swimming pool and gym.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced DPP
Description: Enhanced DPP components consist of access to a mental health counselor, active referrals to mental health services, and traditional healing workshops such as the use of talking circles, a modified photo voice and digital storytelling to address specific psychosocial issues that are a result of historical trauma, stress, and grief.
Study: NCT03032445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcoholic Beer
Description: Subject will be asked to consume alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non alcoholic beer
Description: Subject will be asked to consume non alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
Study: NCT02145598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
Study: NCT03957876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
Study: NCT04280874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone 0.5 MG
Description: 0.5mg dinoprostone applied intracervically

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly
Description: 2mg dinoprostone applied intravaginally
Study: NCT03300778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controlled group
Description: 6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
Study: NCT01979939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325
Study: NCT00665769

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypercapnia
Description: transcutaenous CO2 50-60 mm Hg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normocapnia
Description: transcutaneous CO2 35-45 mm Hg
Study: NCT03629912

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Socially-Based Exercise Intervention for Older Adults
Description: A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socially-Based Exercise Intervention for Older Adults
Description: A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Socially-Based Exercise Intervention for Older Adults
Description: A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
Study: NCT04218396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality use during painful bedside procedure
Description: Virtual reality (VR) will be used in addition to standard analgesic practices during painful bedside procedures. A head mounted display (HMD, Oculus Go Model #1KWPH812PN8354) and noise-cancelling headphones (Sony Model #MDRZ110B) will be provided to the patient during the procedure. This unit involves the patient wearing VR goggles, noise-cancelling headphones, and using a smartphone-based program with various applications the patient can choose from for analgesia/relaxation (eg: calming imagery/scenery of nature, activities involving mindfulness, interactive games or guided imagery, music and imagery, exercise imagery...etc). There are numerous, standard applications available for the patient to choose from, and the choice of most optimal application for analgesia, distraction, or anxiolysis will be left to the decision of the patient prior to their procedure.
Study: NCT03305185

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Schroth SSE with Bracing
Description: Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bracing alone
Description: Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
Study: NCT03181412

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire
Description: Tests from Cincinnati prehospital stroke severity scale (CPSSS) will be carried out by the physician at emergency medical services on telephone call with firemen, paramedics or the emergency medical services team for any stroke suspicion that meets the criteria for inclusion. Emergency department physician will have to follow a standardized questionnaire to complete the different items of the score. The score will not be calculated by emergency department physician and will not influence the orientation and management of patients.~The final diagnosis will be the presence or absence of a large vessel occlusion. This diagnosis will be done on cerebral imaging by a neurologist.
Study: NCT02031419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: 2mg or 3 mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: 2mg or 3 mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: 20mg or 30mg administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: 2mg or 3mg administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292
Description: 500 mg twice a day administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: 20mg or 30mg per day administered orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292
Description: 500 mg twice a day administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once every 28 days
Study: NCT01786889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood and urine
Description: Blood collection and urine collection after consent of the patient

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: The patient complete the questionnaire alone at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone interview
Description: The patient will be contacted by the CRA for a telephone interview of around one hour
Study: NCT03479801

Intervention type: PROCEDURE
Intervention: Thyroid Surgical Methods
Description: Different methods of thyroid surgery, including conventional open thyroidectomy, transoral endoscopic thyroidectomy via vestibular approach, and endoscopic thyroidectomy via breast approach.

Intervention type: PROCEDURE
Intervention: Thyroid Surgical Methods
Description: Different methods of thyroid surgery, including conventional open thyroidectomy, transoral endoscopic thyroidectomy via vestibular approach, and endoscopic thyroidectomy via breast approach.

Intervention type: PROCEDURE
Intervention: Thyroid Surgical Methods
Description: Different methods of thyroid surgery, including conventional open thyroidectomy, transoral endoscopic thyroidectomy via vestibular approach, and endoscopic thyroidectomy via breast approach.
Study: NCT01533194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wild-type Reovirus
Description: Given IV
Study: NCT03229291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04755
Description: SM04755 is a small molecule inhibitor of the Wnt pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04755
Description: SM04755 is a small molecule inhibitor of the Wnt pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04755
Description: SM04755 is a small molecule inhibitor of the Wnt pathway.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Same formulation as topical SM04755 solution, without SM04755 included.
Study: NCT04602468

Intervention type: DRUG
Group type: OTHER
Intervention: Kaftrio
Description: The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.

Intervention type: DRUG
Group type: OTHER
Intervention: Kaftrio
Description: The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
Study: NCT02321163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES new paradigm
Description: stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES conventional
Description: stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NMES no stimulation
Description: Placebo, electrode pad on, no stimulation
Study: NCT00323804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2b
Description: PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin-Placebo
Description: Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
Study: NCT01126385

Intervention type: DEVICE
Intervention: DensiProbe Spine
Description: Intraoperative DensiProbe Spine measurements
Study: NCT02337855

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
Study: NCT04218396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality use during painful bedside procedure
Description: Virtual reality (VR) will be used in addition to standard analgesic practices during painful bedside procedures. A head mounted display (HMD, Oculus Go Model #1KWPH812PN8354) and noise-cancelling headphones (Sony Model #MDRZ110B) will be provided to the patient during the procedure. This unit involves the patient wearing VR goggles, noise-cancelling headphones, and using a smartphone-based program with various applications the patient can choose from for analgesia/relaxation (eg: calming imagery/scenery of nature, activities involving mindfulness, interactive games or guided imagery, music and imagery, exercise imagery...etc). There are numerous, standard applications available for the patient to choose from, and the choice of most optimal application for analgesia, distraction, or anxiolysis will be left to the decision of the patient prior to their procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment during painful bedside procedure
Description: Pharmacologic sedation or high dose opioids (e.g. nurse-administered IV opioids, anxiolytics and sedatives, patient-controlled analgesia, anesthesiologist administered sedation, general anesthesia if required)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment during painful bedside procedure
Description: Pharmacologic sedation or high dose opioids (e.g. nurse-administered IV opioids, anxiolytics and sedatives, patient-controlled analgesia, anesthesiologist administered sedation, general anesthesia if required)
Study: NCT02263261

Intervention type: OTHER
Group type: OTHER
Intervention: Flex HD Pliable Perforated HADM
Description: Human Acellular Dermal Matrix
Study: NCT01665352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP054
Description: Administered orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP054
Description: Administered orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP054
Description: Administered orally once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily for 12 weeks.
Study: NCT00774020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 5mg, i.v. single dose
Study: NCT04576689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBE-814 70ug
Description: Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBE-814 140ug
Description: Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
Study: NCT03855852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft and Collagen membrane
Description: Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Xenograft and APRF
Description: Placing the implant with APRF and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
Study: NCT00869401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
Study: NCT01992562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziconotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04714996

Intervention type: DRUG
Group type: OTHER
Intervention: Open-Label Extension Study
Description: Dosing will be at the discretion of the Investigator with a minimum dose of 25 mg/day (25 mg qd) to a maximum dose of 150 mg/day (75 mg bid).
Study: NCT01166477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir and ritonavir
Description: The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
Study: NCT03511469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Control Group: Standart rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic Group
Description: Concentric group: Standart rehabilitation + isokinetic training
Study: NCT00366327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Description: Flex dose (20 or 30 mg)tablet, QD for 1 year
Study: NCT01380704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-436
Description: QD Days 1-7
Study: NCT01166477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple therapy with ritonavir
Description: The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
Study: NCT00589316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Given via central line
Study: NCT01380704

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: QD Days 1-7
Study: NCT01964677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)
Study: NCT04928560

Intervention type: DIAGNOSTIC_TEST
Intervention: SMI
Description: ULTRASOUND

Intervention type: DIAGNOSTIC_TEST
Intervention: SMI
Description: ULTRASOUND
Study: NCT03006887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: lenvatinib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab intravenous infusion
Study: NCT03489512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (Chloraprep)
Description: Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B (Clorhexidine 2%)
Description: Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
Study: NCT03233126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
Study: NCT01300988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant (Emend®) 375 mg daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant placebo
Description: Aprepitant(Emend®) placebo for 14 days
Study: NCT04229836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg Solution for Injection
Description: Participants will be treated with tildrakizumab 100 mg.